-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Despite advances in medication, most patients with advanced Crohn's disease (CD) still need to be surgically removed.
some patients will relapse after surgery during the course of the disease.
smoking, past surgery, penetrating and diseases during surgery are risk factors for clinical and surgical recurrence after resection.
, however, recent team studies have identified inflammation at the cutting edge as a new independent risk factor for recurrence.
the purpose of this study was to assess the predicted value of small inflammations (including active inflammation, intermuscular plexus and granuloma) on the clinical and surgical recurrence of CD patients at the edge of re-blind bowel removal.
researchers reviewed the removal of cut-edge specimens from 106 consecutive patients with crohn's disease who undergoes a back-blind bowel excision, and rated active inflammation, intermuscular neuritis, and granuloma.
pathological results associated with recurrence are defined as the use of multivariative analysis through endoscopy (improved Rutgeerts score ≥i2) to expand the activity of relapsed diseases around the drug treatment paradigm.
results showed that the proportion of active inflammation was 27% and 15% respectively at the edge of near-end and far-end excision, 37% and 32% respectively, and 4% and 6% respectively.
47 of the 106 patients who had relapsed.
only active inflammation of the far end of the colon to remove the edge is an independent and significant predictor of recurrence (far end, near end and non-exhaustive edges are 88% vs 43% vs 51% ;P slt;0.01, respectively).
the study's final authors said: 'Active inflammation at the far end of the colon after return to the blind bowel removal can identify the matching site and the group of high-risk patients who relapse after colon surgery because it identifies undiagnosed L3 disease.'
these patients have different and more aggressive natural medical histories and require more in-depth treatment.
, the pathological evaluation of the remote excision cut should be carried out in daily practice.
.